A clinical pharmacology study of CH5424802 (JP28927)
Phase 1
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-jRCT2080222140
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
NSCLC
-ECOG PS 0-1
-ALK-positive
Exclusion Criteria
-Prior treatment with CH5424802
-Meningeal metastases or brain metastases that are symptomatic or requiring treatment
-Pregnatnt or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method